vs

Side-by-side financial comparison of MAXLINEAR, INC (MXL) and RIGEL PHARMACEUTICALS INC (RIGL). Click either name above to swap in a different company.

MAXLINEAR, INC is the larger business by last-quarter revenue ($137.2M vs $69.8M, roughly 2.0× RIGEL PHARMACEUTICALS INC). RIGEL PHARMACEUTICALS INC runs the higher net margin — 384.0% vs -32.9%, a 416.9% gap on every dollar of revenue. On growth, MAXLINEAR, INC posted the faster year-over-year revenue change (43.0% vs 21.2%). Over the past eight quarters, RIGEL PHARMACEUTICALS INC's revenue compounded faster (53.7% CAGR vs 22.1%).

MaxLinear, Inc. is an American electronic hardware company. Founded in 2003, it provides highly integrated radio-frequency (RF) analog and mixed-signal semiconductor products for broadband communications applications. It is a New York Stock Exchange-traded company.

Rigel Pharmaceuticals Inc is a clinical-stage biotechnology company focused on developing and commercializing targeted small molecule therapies for autoimmune, inflammatory, and hematologic diseases. Its approved flagship product treats adult immune thrombocytopenia, with primary operations and core markets in the United States, addressing unmet medical needs for underserved patient groups.

MXL vs RIGL — Head-to-Head

Bigger by revenue
MXL
MXL
2.0× larger
MXL
$137.2M
$69.8M
RIGL
Growing faster (revenue YoY)
MXL
MXL
+21.8% gap
MXL
43.0%
21.2%
RIGL
Higher net margin
RIGL
RIGL
416.9% more per $
RIGL
384.0%
-32.9%
MXL
Faster 2-yr revenue CAGR
RIGL
RIGL
Annualised
RIGL
53.7%
22.1%
MXL

Income Statement — Q1 FY2026 vs Q4 FY2025

Metric
MXL
MXL
RIGL
RIGL
Revenue
$137.2M
$69.8M
Net Profit
$-45.1M
$268.1M
Gross Margin
57.5%
91.5%
Operating Margin
30.0%
33.2%
Net Margin
-32.9%
384.0%
Revenue YoY
43.0%
21.2%
Net Profit YoY
-203.0%
1769.2%
EPS (diluted)
$-0.52
$14.11

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
MXL
MXL
RIGL
RIGL
Q1 26
$137.2M
Q4 25
$136.4M
$69.8M
Q3 25
$126.5M
$69.5M
Q2 25
$108.8M
$101.7M
Q1 25
$95.9M
$53.3M
Q4 24
$92.2M
$57.6M
Q3 24
$81.1M
$55.3M
Q2 24
$92.0M
$36.8M
Net Profit
MXL
MXL
RIGL
RIGL
Q1 26
$-45.1M
Q4 25
$-14.9M
$268.1M
Q3 25
$-45.5M
$27.9M
Q2 25
$-26.6M
$59.6M
Q1 25
$-49.7M
$11.4M
Q4 24
$-57.8M
$14.3M
Q3 24
$-75.8M
$12.4M
Q2 24
$-39.3M
$-1.0M
Gross Margin
MXL
MXL
RIGL
RIGL
Q1 26
57.5%
Q4 25
57.6%
91.5%
Q3 25
56.9%
93.2%
Q2 25
56.5%
95.6%
Q1 25
56.1%
91.7%
Q4 24
55.6%
89.9%
Q3 24
54.4%
85.5%
Q2 24
54.6%
92.4%
Operating Margin
MXL
MXL
RIGL
RIGL
Q1 26
30.0%
Q4 25
-10.9%
33.2%
Q3 25
-32.7%
40.9%
Q2 25
-22.6%
60.1%
Q1 25
-48.0%
23.9%
Q4 24
-44.7%
28.9%
Q3 24
-82.3%
25.4%
Q2 24
-44.4%
1.2%
Net Margin
MXL
MXL
RIGL
RIGL
Q1 26
-32.9%
Q4 25
-10.9%
384.0%
Q3 25
-36.0%
40.2%
Q2 25
-24.4%
58.6%
Q1 25
-51.8%
21.5%
Q4 24
-62.8%
24.9%
Q3 24
-93.4%
22.5%
Q2 24
-42.7%
-2.8%
EPS (diluted)
MXL
MXL
RIGL
RIGL
Q1 26
$-0.52
Q4 25
$-0.17
$14.11
Q3 25
$-0.52
$1.46
Q2 25
$-0.31
$3.28
Q1 25
$-0.58
$0.63
Q4 24
$-0.68
$0.82
Q3 24
$-0.90
$0.70
Q2 24
$-0.47
$-0.06

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
MXL
MXL
RIGL
RIGL
Cash + ST InvestmentsLiquidity on hand
$61.1M
$155.0M
Total DebtLower is stronger
$123.8M
$52.5M
Stockholders' EquityBook value
$454.2M
$391.5M
Total Assets
$771.3M
$513.6M
Debt / EquityLower = less leverage
0.27×
0.13×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
MXL
MXL
RIGL
RIGL
Q1 26
$61.1M
Q4 25
$72.8M
$155.0M
Q3 25
$111.9M
$137.1M
Q2 25
$108.6M
$108.4M
Q1 25
$102.8M
$77.1M
Q4 24
$118.6M
$77.3M
Q3 24
$148.5M
$61.1M
Q2 24
$185.1M
$49.1M
Total Debt
MXL
MXL
RIGL
RIGL
Q1 26
$123.8M
Q4 25
$52.5M
Q3 25
$60.0M
Q2 25
$60.0M
Q1 25
$60.0M
Q4 24
$60.0M
Q3 24
$60.0M
Q2 24
$60.0M
Stockholders' Equity
MXL
MXL
RIGL
RIGL
Q1 26
$454.2M
Q4 25
$451.9M
$391.5M
Q3 25
$464.7M
$117.6M
Q2 25
$488.3M
$81.9M
Q1 25
$493.2M
$18.6M
Q4 24
$516.3M
$3.3M
Q3 24
$556.9M
$-14.6M
Q2 24
$617.3M
$-29.9M
Total Assets
MXL
MXL
RIGL
RIGL
Q1 26
$771.3M
Q4 25
$796.4M
$513.6M
Q3 25
$808.1M
$242.5M
Q2 25
$863.7M
$206.7M
Q1 25
$855.3M
$176.0M
Q4 24
$864.6M
$164.0M
Q3 24
$895.3M
$139.4M
Q2 24
$973.2M
$128.4M
Debt / Equity
MXL
MXL
RIGL
RIGL
Q1 26
0.27×
Q4 25
0.13×
Q3 25
0.51×
Q2 25
0.73×
Q1 25
3.23×
Q4 24
18.25×
Q3 24
Q2 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
MXL
MXL
RIGL
RIGL
Operating Cash FlowLast quarter
$22.0M
Free Cash FlowOCF − Capex
FCF MarginFCF / Revenue
Capex IntensityCapex / Revenue
Cash ConversionOCF / Net Profit
0.08×
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
MXL
MXL
RIGL
RIGL
Q1 26
Q4 25
$10.4M
$22.0M
Q3 25
$10.1M
$24.0M
Q2 25
$10.5M
$30.5M
Q1 25
$-11.4M
$-893.0K
Q4 24
$-27.8M
$14.5M
Q3 24
$-30.7M
$21.7M
Q2 24
$-2.7M
$302.0K
Free Cash Flow
MXL
MXL
RIGL
RIGL
Q1 26
Q4 25
$6.7M
Q3 25
$4.4M
Q2 25
$9.3M
Q1 25
$-13.4M
Q4 24
$-30.0M
Q3 24
$-34.9M
Q2 24
$-5.7M
FCF Margin
MXL
MXL
RIGL
RIGL
Q1 26
Q4 25
4.9%
Q3 25
3.5%
Q2 25
8.6%
Q1 25
-14.0%
Q4 24
-32.6%
Q3 24
-43.0%
Q2 24
-6.2%
Capex Intensity
MXL
MXL
RIGL
RIGL
Q1 26
Q4 25
2.7%
Q3 25
4.5%
Q2 25
1.1%
Q1 25
2.1%
Q4 24
2.4%
Q3 24
5.1%
Q2 24
3.3%
Cash Conversion
MXL
MXL
RIGL
RIGL
Q1 26
Q4 25
0.08×
Q3 25
0.86×
Q2 25
0.51×
Q1 25
-0.08×
Q4 24
1.01×
Q3 24
1.75×
Q2 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons